[Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. I. Isolation and structure elucidation of urinary metabolite in dog].
The urinary metabolites of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoat e (Y-20811) in dog were investigated. The main metabolite was isolated by high performance liquid chromatography and subsequent preparative thin layer chromatography. The structure of this metabolite was established as 4-[alpha-hydroxy-2-hydroxymethyl-5-(1-imidazolyl)benzyl]-3,5- dimethylbenzoic acid on the basis of spectral analyses and confirmed by its total synthesis.
Iwata
T
T
Tsuruda
M
M
Demizu
K
K
Isobe
M
M
Takamatsu
R
R
Yokobe
T
T
D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D004285:Dogs; D007093:Imidazoles / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000652:urine*; D013057:Spectrum Analysis; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007093:Imidazoles; C049966:Y 20811; D013930:Thromboxane-A Synthase